(5α)-androstane-3β,17β-diol | 571-20-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (5α)-androstane-3β,17β-diol
• 英文别名: piandrosterone；3β,17β-Dihydroxy-5α-androstan；5α-Androstandiol-(3β,17β)；5α-Androstan-3β,17β-diol；Androstandiol-(3β,17β)；(3S,5S,10S,13S,17S)-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,17-diol
• CAS: 571-20-0；1851-23-6；1852-53-5；4069-06-1；4069-07-2；5856-10-0；5856-11-1；5864-32-4；6038-31-9；6165-21-5；16989-87-0；16989-88-1；18485-82-0；18485-84-2；19767-69-2；19905-98-7；21862-73-7；21862-74-8；25126-76-5；28980-34-9；33526-31-7；33526-32-8；34864-27-2；54324-44-6；55821-63-1；55821-64-2；55821-65-3；62356-64-3；65451-37-8；87099-87-4；87099-93-2；94667-48-8；95975-22-7
• 化学式: C₁₉H₃₂O₂
• 分子量: 292.462
• InChiKey: CBMYJHIOYJEBSB-ARKAXQQOSA-N

物化性质

• 熔点：
  236-236.5 °C
• 沸点：
  374.38°C (rough estimate)
• 密度：
  1.0164 (rough estimate)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24,S45
• 危险类别码：
  R36/38
• RTECS号：
  BV8044320

制备方法与用途

用途：用于合成性激素的原料

文献信息

• INDOMETHACIN ANALOGS FOR THE TREATMENT OF CASTRATE-RESISTANT PROSTATE CANCER
  申请人：Vanderbilt University

  公开号：US20140371261A1

  公开（公告）日：2014-12-18

  Provided are compositions for inhibiting a biological activity of an aldoketo reductase family 1, member C3 (AKR1 C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1 C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.

  提供了一些用于抑制醛酮还原酶家族1成员C3（AKR1 C3）多肽生物活性的组合物。在某些实施例中，这些组合物是AKR1 C3特异性抑制剂的吲哚美辛衍生物。还提供了制备所述吲哚美辛衍生物的方法，这些方法基本上缺乏环氧合酶抑制活性，但具有AKR1C3抑制活性，以及抑制AKR1C3多肽生物活性的方法和治疗受试者的前列腺肿瘤的方法。
• Indomethacin analogs for the treatment of castrate-resistant prostate cancer
  申请人：Vanderbilt University

  公开号：US10398678B2

  公开（公告）日：2019-09-03

  Provided are compositions for inhibiting a biological activity of an aldo-keto reductase family 1, member C3 (AKR1C3) polypeptide. In some embodiments, the compositions are indomethacin derivatives that are AKR1C3-specific inhibitors. Also provided are methods for producing disclosed indomethacin derivatives that substantially lack cyclooxygenase inhibitory activity but that have AKR1C3 inhibitory activity, methods for inhibiting AKR1C3 polypeptide biological activities, and methods for treating prostate tumors in subjects.

  本文提供了用于抑制醛酮还原酶家族 1 成员 C3（AKR1C3）多肽生物活性的组合物。在某些实施方案中，这些组合物是 AKR1C3 特异性抑制剂的吲哚美辛衍生物。还提供了生产所公开的基本上缺乏环氧化酶抑制活性但具有AKR1C3抑制活性的吲哚美辛衍生物的方法、抑制AKR1C3多肽生物活性的方法以及治疗受试者前列腺肿瘤的方法。
• Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20220339176A1

  公开（公告）日：2022-10-27

  Methods of treatment for menstrual complications, gestational complications, and to prolong gestation are described. Treatments include administration of a compound related to regulation of gestational progress or uterine contractions.
• US9346803B2
  申请人：——

  公开号：US9346803B2

  公开（公告）日：2016-05-24
• US9895351B2
  申请人：——

  公开号：US9895351B2

  公开（公告）日：2018-02-20